Csepp-Med Kft.
- Address
- II RakoczI Ferenc Ut 107-115 D Lhaz 1 Em 11 Ajto, 1211 Budapest, Hungary
Cardiovascular Disease Therapeutics
The site focuses on advancing care for patients with atherosclerotic cardiovascular disease and related conditions, including hypertension and high cardiovascular risk.
- Assessing the long‑term safety and tolerability of pelacarsen in individuals with elevated Lp(a) and established CVD
- Evaluating whether zilebesiran can lower the incidence of cardiovascular death, myocardial infarction, stroke, or heart‑failure events
- Investigating treatment strategies for uncontrolled hypertension in patients with existing cardiovascular disease
- Studying risk‑reduction approaches for patients at high cardiovascular risk
Csepp-Med Kft., located in Budapest, Hungary, conducts these investigator‑led studies within a non‑commercial hospital setting, aiming to improve outcomes for cardiovascular patients across Europe.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Alnylam Pharmaceuticals Inc.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Csepp-Med Kft.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Long-term Safety and Tolerability Evaluation of Pelacarsen in Patients with Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease | Novartis Pharma AG | Phase III | Recruiting | May 2026 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pelacarsen | 1 | Unknown | 2026-05-11 | 2026-05-11 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.